- Details
- Andrea Miyahira interviews Michael Haffner about his group's study on the expression of TROP2, CEACAM5, and DLL3 in metastatic prostate cancer, published in NEJM Evidence. Dr. Haffner discusses their analysis of over 750 samples from 52 patients in a rapid autopsy cohort, examining protein expression across different molecular subtypes of castration-resistant prostate cancer. The study reveals dis...
|
- Details
- Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
|
- Details
- Ruchika Talwar hosts Daniel Triner to discuss a study on the management of lymph node-positive prostate cancer after radical prostatectomy. Using data from the Michigan Urological Surgery Improvement Collaborative (MUSIC), Dr. Triner's team analyzes treatment patterns for 666 patients. They find that approximately two-thirds of patients receive secondary treatment within 12 months, with variations...
|
- Details
- Alicia Morgans interviews Omar El-Taji and Ashwin Sachdeva about their JAMA Oncology publication on cardiovascular risks associated with androgen receptor signaling inhibitors (ARSIs) in prostate cancer treatment. Their meta-analysis reveals that ARSIs significantly increase the risk of cardiovascular events across all stages of prostate cancer, with abiraterone and enzalutamide showing the highes...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
- Details
- Matthew Smith presents the primary analysis of the CYCLONE 2 trial. This global randomized controlled trial investigated the combination of abemaciclib, a CDK4/6 inhibitor, with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). Despite the promising biological rationale and preclinical evidence suggesting potential benefits, the trial did...
|
- Details
- Alicia Morgans speaks with Zach Klaassen about his research focusing on the intersection of mental health and prostate cancer care in the veterans’ population. Dr. Klaassen shares insights from his extensive study aimed at creating the world's largest prostate cancer mental health database. Initial findings reveal that veterans with mental health issues are less frequently diagnosed with prostate...
|
- Details
- Zach Klaassen and Stacy Loeb discuss the IMPLEMENT Study, which investigates the underutilization of treatment intensification in metastatic hormone-sensitive prostate cancer. Despite guidelines recommending this approach, it is used in less than a third of cases. Phase one of the study identified barriers like limited knowledge of clinical trials and concerns about using up treatment options earl...
|
- Details
- Ali Sabbagh presents a novel study on using machine learning to predict overall survival in clinical trials for metastatic prostate cancer. Dr. Sabbagh explains that traditional endpoints like overall survival often require long follow-ups, delaying access to potentially life-saving treatments. His research leverages baseline clinical characteristics and PSA changes over four months to accelerate...
|
- Details
- Rahul Aggarwal presents findings on targeting DLL3 in neuroendocrine prostate cancer. He explains that DLL3 is highly expressed in high-risk neuroendocrine prostate cancer, particularly in the treatment-emergent form seen after androgen deprivation therapy. This Phase 1b study expanded on prior research in small cell lung cancer and included 40 patients with broad inclusion criteria for DLL3 posit...
|
